口蹄疫双佐剂灭活疫苗的研究

Research on Double Adjuvant Inactivated FMDV Vaccines

在口蹄疫二价灭活疫苗(O型、AsiaⅠ型)常规使用法国SEPPIC公司206佐剂的基础上,设计了一种缓释作用更强的双佐剂成分疫苗。通过MTT法检测淋巴细胞增殖能力、液相阻断ELISA法检测口蹄疫抗体效价及攻毒试验测定PD50来评判该双佐剂疫苗与常规疫苗的效果差异。结果显示,双佐剂疫苗组细胞免疫水平(淋巴细胞刺激指数SI为1.235±0.060)比常规佐剂疫苗组(SI为1.115±0.035)和对照组(SI为1.010±0.045)高,与常规疫苗组相比差异显著(P<0.05),与空白对照组相比,差异极显著(P<0.01)。双佐剂疫苗组O型和AsiaⅠ型抗体与常规佐剂疫苗组相比,全剂量组抗原量较充分,两组抗体水平差距不大;1/3剂量组和1/9剂量组由于抗原量较少和强缓释作用,导致抗体水平明显较低。攻毒保护结果为双佐剂疫苗组略高于常规佐剂疫苗组,前者每头份疫苗AsiaⅠ型为9.0 PD50,O型为11.84 PD50,后者每头份疫苗AsiaⅠ型为9.0PD50,O型为9.0 PD50。由分析结果可见,双佐剂疫苗可引起较好的细胞免疫应答和缓释作用,达到好的攻毒保护效果。

On the basis of foot and mouth disease virus （FMDV） inactivated bivalent（O type, Asia I type） vaccines（called conventional FMDV vaccines blew ） using 206 adjuvant （France SEPPIC company）, a double adjuvant inactivated bivalent FMDV vaccines was designed, it possessed stronger delayed release effeet than conventional FMDV vaccines. According to the lymphocytes proliferation reaction （MTT）, LP-ELISA and challenge protection experiments,the lymphocytes stimulation indices （SI= 1. 235±0. 060） of double adjuvant vaccines group was higher than conventional FMDV vaccines group （SI= 1.115±4- 0. 035）and control group （SI=1. 010±-0. 045） ; compared with conventional FMDV vaccines group and control group, the celluar immunity level of double adiuvant vaccines group was significant than conventional one （P〈0.05） and significant stronger than control one （P〈0.01）. However, as full dose immunity, antibody titer of conventional FMDV vaccines and double adjuvant vaccines group had little difference, 1/3 dose and 1/9 close groups were especially lower than above two groups for less antigen and strong delayed release effect. The results of challenge protection efficiency showed that conventional adjuvant vaccines group was a little higher than the FMDV vaccines group, the former O strain was 11.84 PDs0and Asia I strain was 9.0 PD50 the latter O strain and Asia I strain all were 9.0 PD50. The results suggested that double adjuvant vaccines could induce better cellular immunity, possessed stronger delayed release effect and supported better challenge protection efficiency than conventional FMDV vaccines.